
Edit design

Add Roy’s parts


**Question 1**


**Q1.1**




Comparing the four cancers by patients’ race, and modifying the comparison accordingly to the question, we feel safe to claim that the Native Hawaiian or Other Pacific Islander race group **is** **predisposed** to a specific type of cancer – which is ***Endometrial cancer***.

From our comparison analysis, we got the following table:





In addition, we got the following 100% stacked barplot generated from this analysis:




Looking at these results (the table and the plot), we may notice that the distribution for different cancer types among the *Native Hawaiian or Other Pacific Islander* race group differs greatly from its equivalent among other race group.

Even more than that – we may notice that over 80% of the patients in this race group suffer from Endometrial Carcinoma, which might lead us to determine that the race group seems to be predisposed to this specific type of cancer.


It is important to add that this is **not conclusive**. In order to claim such thing with higher confidence, we could have used a larger dataset or investigate other factors that could have been the cause for that correspondence.

**Q1.2**




Comparing between overall survival statuses of the patients in the four cancers by cancer type, we see that the tumor type with the lowest median of overall survival time is **Ovarian Epithelial cancer**.

We chose to add the following table:




From the table, we understand that the lowest median months survival for any type of cancer (among the four cancers chosen for our analysis) is ***45.14 months***, and is received for patients with the **Ovarian Epithelial Tumor**.

Here is another graph that helps us come to this conclusion:




Add something?

Q1.3



The gene with the highest frequency of copy number alterations (i.e. CNA) in this combined study is **MYC** (with a frequency of ***16.6%***).

This can be easily found with looking at the following table:




MYC gene’s functional role in the cell is encoding a multifunctional, nuclear phosphoprotein that controls a variety of cellular functions, including cell cycle, cell growth, apoptosis, cellular metabolism and biosynthesis, adhesion, and mitochondrial biogenesis – as MYC (MYC Proto-Oncogene, BHLH Transcription Factor) is a protein coding gene.

As we read a little online about the gene, we discovered that MYC has several diseases associated with it.


Cancer being one of those, we learned that MYC might induce tumorigenesis by evading multiple tumor-suppressing checkpoint mechanisms, including proliferative arrest, apoptosis, and/or senescence. On MYC suppression these barriers are restored, enabling sustained tumor regression.

Q1.4




Relying on this comparison/survival analysis, while querying the combined studies (for the MYC gene found in 1.3), we can say that in the four cancers, the progression free survival data differs significantly with the altered MYC gene versus the unaltered genes group.

We decided to have a look at the following graph:



This graph tells us that the percentage of progression free survival among patient with the altered MYC gene is much lower than the equivalent percentage among the unaltered group, over time. *For example, we see that after 200 months the difference is between around 20% to over 40%.*


**Q1.5**




In this section, we have browsed each cancer type separately for its progression free plot of the MYC gene versus the unaltered genes group.

You may enjoy them as well:


**Breast Invasive Carcinoma-**




**Cervical Squamous Cell Carcinoma-**




**Ovarian Serous Cystadenocarcinoma-**



**Uterine Corpus Endometrial Carcinoma-**






In this section, we have browsed each cancer type separately for its progression free plot of the MYC gene versus the unaltered genes group.

Relying on the plots in front of us, it seems that the MYC gene may be connected to the progression free survival of one type of cancer significantly more than the other three – and that is the ***Uterine Corpus Endometrial Carcinoma***.

In 1.4, we saw that the progression free survival of patients with the MYC gene altered is lower than the equivalent of patients in the unaltered group. Browsing for each the connection between the gene and each cancer individually helps us come to an important conclusion-

It seems that the difference in the progression free survival percentage it caused by the Uterine Corpus Endometrial Carcinoma specifically, as the other three types of cancer do not demonstrate the same reduction in percentage.

**Q1.6**



In total, the gene is altered in ~17% of queried patients/samples (as calculated in *cBioPortal*).

The most abundant genetic alteration in the MYC gene for all four cancers analyzed is in the **Ovarian Serous Cystadenocarcinoma**.

Observing the plot attached at the end of this section, we notice that the gene is altered over 30% of the patients with this type of cancer, while it is altered in less than 15% of patients with all other three types of cancer.

